Advenchen Pharmaceuticals LLC

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

1 Completed trials

2 Countries active

1 Unique IMPs

100% Results reported

Phase II

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Small cell lung cancer 2

Top IMPs

All trials

2 total

Evaluation of the safety and efficacy of the drug AL8326 in the post-first treatment of small cell lung cancer. Not authorised

2023-509067-24-00 Phase II 2 countries AL8326
Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Ended

2023-509067-24-01 Phase II 2 countries AL8326

Showing 1–2 of 2 trials

← All sponsors A–Z